CLL patient characteristics (n = 22)
| Patient characteristics . | CLL disease features . | CLL transplantation features . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SPN . | Age, y . | Sex . | Cytogenetics by FISH . | Fludarabine refractory* . | CLL VH-IgG . | No. of prior regimens . | Mos from prior R . | Alemtuzumab before HCT . | CLL Status at HCT . | LN > 5cm before HCT . | BM CLL, %CD45 . | Time from diagnosis to HCT, mo . | Donor sex/age, y . | RD/URD . |
| 3399 | 65 | M | 11q−13q− | N | Unmutated† | 3 | 17 | N | PR | N | 15 | 67 | F/55 | RD |
| 3409 | 55 | M | NA | Y | Unmutated | 3 | 1 | N | PR | N | 50 | 9 | M/50 | RD |
| 3431 | 46 | F | 11q 13q− 17p− | N | Unmutated | 4 | 1 | Y | PD | Y | 10 | 30 | F/53 | RD |
| 3455 | 57 | F | complex cyto | Y | Unmutated | 5 | 23 | Y | PR | N | 2 | 66 | F/21 | URD |
| 3515 | 64 | M | 11q− 13q− | Y | ND | 2 | 15 | Y | PR | N | 4 | 29 | M/62 | RD |
| 3632 | 46 | M | 17p− | Y | Unmutated | 3 | 12 | Y | PR | N | 1 | 51 | F/38 | URD-DQ allele MM |
| 3697 | 54 | F | NA | N | Unmutated | 1 | 7 | N | PR | N | 5 | 9 | F/55 | RD |
| 3703 | 64 | M | NA | N | Unmutated | 4 | 2 | N | PR | N | 10 | 57 | M/25 | URD |
| 3719 | 61 | M | 11q− 17p− | N | ND | 1 | 8 | Y | CR | N | 0 | 15 | F/22 | URD |
| 3723 | 44 | F | 17p− complex cyto | Y | Unmutated | 2 | 2 | N | PD | Y | 50 | 48 | F/22 | URD |
| 3732 | 51 | M | 6q− 13q− +11 | Y | Unmutated | 3 | 3 | N | PR | Y | 30 | 29 | F/50 | RD |
| 3740 | 58 | F | 17p− | Y | Unmutated | 5 | 1 | N | PR | Y | 80 | 128 | M/56 | RD |
| 3751 | 56 | M | 17p− | Y | Unmutated | 6 | 2 | Y | PR | N | < 1 | 43 | M/26 | URD |
| 3835 | 64 | M | 13q− 17p− | Y | Unmutated | 2 | 1 | N | CR | N | 0 | 10 | M/36 | URD |
| 3855 | 31 | M | NA | Y | Unmutated | 2 | 30 | N | PD | N | 35 | 79 | F/55 | URD-DQ,DP MM |
| 3870 | 50 | M | NA | N | Unmutated | 2 | 6 | N | CR | N | 0 | 27 | M/46 | RD |
| 3873 | 59 | F | 13q− | N | Unmutated | 4 | 2 | Y | PR | N | 50 | 82 | M/53 | RD |
| 3879 | 43 | F | NA | Y | Mutated | 5 | 1 | N | PR | N | 20 | 195 | F/36 | RD |
| 3903 | 50 | M | 13q− | Y | Unmutated | 3 | 10 | Y | PR | N | 2 | 16 | M/22 | URD |
| 3926 | 54 | M | 13q− | Y | Mutated | 3 | 2 | N | PR | N | 0 | 55 | F/57 | URD |
| 3934 | 60 | M | 11q− 13q− | Y | Unmutated | 7 | 1 | Y | PR | N | 10 | 110 | M/57 | RD |
| 3975 | 48 | M | 17p− | Y | Unmutated | 3 | 5 | Y | CR | N | 0 | 60 | F/41 | RD |
| Patient characteristics . | CLL disease features . | CLL transplantation features . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SPN . | Age, y . | Sex . | Cytogenetics by FISH . | Fludarabine refractory* . | CLL VH-IgG . | No. of prior regimens . | Mos from prior R . | Alemtuzumab before HCT . | CLL Status at HCT . | LN > 5cm before HCT . | BM CLL, %CD45 . | Time from diagnosis to HCT, mo . | Donor sex/age, y . | RD/URD . |
| 3399 | 65 | M | 11q−13q− | N | Unmutated† | 3 | 17 | N | PR | N | 15 | 67 | F/55 | RD |
| 3409 | 55 | M | NA | Y | Unmutated | 3 | 1 | N | PR | N | 50 | 9 | M/50 | RD |
| 3431 | 46 | F | 11q 13q− 17p− | N | Unmutated | 4 | 1 | Y | PD | Y | 10 | 30 | F/53 | RD |
| 3455 | 57 | F | complex cyto | Y | Unmutated | 5 | 23 | Y | PR | N | 2 | 66 | F/21 | URD |
| 3515 | 64 | M | 11q− 13q− | Y | ND | 2 | 15 | Y | PR | N | 4 | 29 | M/62 | RD |
| 3632 | 46 | M | 17p− | Y | Unmutated | 3 | 12 | Y | PR | N | 1 | 51 | F/38 | URD-DQ allele MM |
| 3697 | 54 | F | NA | N | Unmutated | 1 | 7 | N | PR | N | 5 | 9 | F/55 | RD |
| 3703 | 64 | M | NA | N | Unmutated | 4 | 2 | N | PR | N | 10 | 57 | M/25 | URD |
| 3719 | 61 | M | 11q− 17p− | N | ND | 1 | 8 | Y | CR | N | 0 | 15 | F/22 | URD |
| 3723 | 44 | F | 17p− complex cyto | Y | Unmutated | 2 | 2 | N | PD | Y | 50 | 48 | F/22 | URD |
| 3732 | 51 | M | 6q− 13q− +11 | Y | Unmutated | 3 | 3 | N | PR | Y | 30 | 29 | F/50 | RD |
| 3740 | 58 | F | 17p− | Y | Unmutated | 5 | 1 | N | PR | Y | 80 | 128 | M/56 | RD |
| 3751 | 56 | M | 17p− | Y | Unmutated | 6 | 2 | Y | PR | N | < 1 | 43 | M/26 | URD |
| 3835 | 64 | M | 13q− 17p− | Y | Unmutated | 2 | 1 | N | CR | N | 0 | 10 | M/36 | URD |
| 3855 | 31 | M | NA | Y | Unmutated | 2 | 30 | N | PD | N | 35 | 79 | F/55 | URD-DQ,DP MM |
| 3870 | 50 | M | NA | N | Unmutated | 2 | 6 | N | CR | N | 0 | 27 | M/46 | RD |
| 3873 | 59 | F | 13q− | N | Unmutated | 4 | 2 | Y | PR | N | 50 | 82 | M/53 | RD |
| 3879 | 43 | F | NA | Y | Mutated | 5 | 1 | N | PR | N | 20 | 195 | F/36 | RD |
| 3903 | 50 | M | 13q− | Y | Unmutated | 3 | 10 | Y | PR | N | 2 | 16 | M/22 | URD |
| 3926 | 54 | M | 13q− | Y | Mutated | 3 | 2 | N | PR | N | 0 | 55 | F/57 | URD |
| 3934 | 60 | M | 11q− 13q− | Y | Unmutated | 7 | 1 | Y | PR | N | 10 | 110 | M/57 | RD |
| 3975 | 48 | M | 17p− | Y | Unmutated | 3 | 5 | Y | CR | N | 0 | 60 | F/41 | RD |
R indicates rituximab; LN, lymph node; RD, matched related donor; URD, unrelated donor; MM, mismatch; NA, not available; ND, not determined; and PD, progressive disease.
Defined as failure to achieve a PR or CR to at least 1 fludarabine-containing regimen, disease progression while on fludarabine treatment, or disease progression within 6 months of the last dose of fludarabine.
Unmutated VH-IgG CLL clone (CLL VH-IgG sequence varies by < 2% from germline).